JARED BRABHAM: Open Payments
NPI 1134763576 · SULPHUR, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 61 payments from 10 companies in 2025. Trend: 2023 $208 · 2024 $484 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $190 |
| Vanda Pharmaceuticals Inc. | 15 | $171 |
| Teva Pharmaceuticals USA, Inc. | 8 | $142 |
| E.R. Squibb & Sons, L.L.C. | 10 | $139 |
| Janssen Pharmaceuticals, Inc | 3 | $78 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Indivior Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Alkermes, Inc. | 1 | $26 |
Products named: VRAYLAR, FANAPT, COBENFY, UZEDY, INVEGA SUSTENNA, AUSTEDO XR, INGREZZA, SUBLOCADE.
Industry payments across LA — which companies pay providers there.
